1

2

3
George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Wellcome, John L Lemanowicz, January 16, 2001: US06174889 (38 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S ...


4
George Stuart Cockerill, Malcolm Clive Carter, Stephen Barry Guntrip, Kathryn Jane Smith: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Wellcome, John L Lemanowicz, March 27, 2001: US06207669 (33 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds in which one ring is a pyridine or pyrimidine of formula (I) are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions inc ...


5
Cockerill George Stuart, Carter Malcolm Clive, Guntrip Stephen Barry, Smith Kathryn Jane: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Group, April 23, 2003: EP1304110-A2 (15 worldwide citation)

Protein tyrosine kinase inhibitor compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds, and their use in medicine, for example in the treatment of cancer and psoriasis. In particular, the use of an inhibitor of both EGFR and erbB-2 in th ...


6
Cockerill George Stuart, Carter Malcolm Clive, Guntrip Stephen Barry, Smith Kathryn Jane: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Group, May 6, 1999: EP0912570-A1 (14 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds of formula (I), wherein X is N or CH; A represents a fused 5, 6 or 7-membered heterocyclic ring containing 1 to 5 heteroatoms which may be the same or different and which are selected from N, O or S ...


7
Malcolm Clive Carter, George Stuart Cockerill, Karen Elizabeth Lackey: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. GlaxoSmithKline, J Scott Young, August 20, 2013: US08513262 (2 worldwide citation)

A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L′ are suitable leaving groups, with a compound of formula (III) UNH2  (III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R1 by ...


8

9
Cockerill George Stuart, Carter Malcolm Clive, Guntrip Stephen Barry, Smith Kathryn Jane: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Group, Cockerill George Stuart, Carter Malcolm Clive, Guntrip Stephen Barry, Smith Kathryn Jane, REED Michael A, January 22, 1998: WO/1998/002437 (1 worldwide citation)

Substituted heteroaromatic compounds, and in particular substituted bicyclic heteroaromatic compounds in which one ring is a pyridine or pyrimidine of formula (I) are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions inc ...


10
Cockerill George Stuart, Guntrip Stephen Barry, Mckeown Stephen Carl, Page Martin John, Smith Kathryn Jane, Vile Sadie, Hudson Alan Thomas, Barraclough Paul, Franzmann Karl Witold: Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors. Glaxo Group, Cockerill George Stuart, Guntrip Stephen Barry, Mckeown Stephen Carl, Page Martin John, Smith Kathryn Jane, Vile Sadie, Hudson Alan Thomas, Barraclough Paul, Franzmann Karl Witold, REED Michael A, April 17, 1997: WO/1997/013771 (1 worldwide citation)

Substituted heteroaromatic compounds of formula (A) wherein X is N or CH; in which (a) represents a fused 5, 6 or 7-membered heterocyclic ring and R?3¿ is a group ZR?4¿ wherein Z is joined to R?4¿ through a (CH¿2?)p group in which p is 0, 1, or 2 and Z represents a group V(CH¿2?), V(CF¿2?), (CH¿2?)V ...